Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Weighted Average) (2021 - 2025)

ARS Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $98.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.68% year-over-year to $98.6 million; the TTM value through Dec 2025 reached $98.6 million, up 1.68%, while the annual FY2025 figure was $98.6 million, 1.68% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $98.6 million at ARS Pharmaceuticals, roughly flat from $98.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $98.6 million in Q4 2025 and bottomed at $28.9 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $94.9 million (2023), against an average of $71.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) dropped 12.67% in 2022 before it soared 210.38% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $28.9 million in 2021, then soared by 38.39% to $40.0 million in 2022, then surged by 138.3% to $95.2 million in 2023, then rose by 1.81% to $96.9 million in 2024, then increased by 1.68% to $98.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Shares Outstanding (Weighted Average) are $98.6 million (Q4 2025), $98.4 million (Q3 2025), and $98.2 million (Q2 2025).